.png)
Paras Kumar Mishra Laboratory
Targeting Diabetic Cardiomyopathy
Prevalence of diabetes mellitus (DM) is rampantly increased and > 400 million population in the world and >30 million population in the USA are diabetic. DM causes cardiac muscle disorder called diabetic cardiomyopathy (DMCM), which increases the risk of heart failure. The chances of DM patients to develop heart failure is ~9 times higher than the non-diabetic patients under the age of 55 years. Recent clinical trials including ACCORD, VA-CSDM Feasibility, and RECORD trials demonstrate that even tightly controlling glucose levels could not decrease the risk of heart failure in DM patients. Thus, there is a dire need to develop a novel therapeutic approach to mitigate diabetic cardiomyopathy.
Our research focuses on understanding the molecular mechanisms underlying diabetic cardiomyopathy and developing a novel therapeutic strategy for diabetic cardiomyopathy. Using microRNA (endogenous, non-coding, regulatory small RNA) approach, we aim to mitigate mitochondria damage (a hallmark of DM heart), adverse cardiac remodeling, and cardiac dysfunction in the DM heart. The other therapeutic strategies includes supplementation of hydrogen sulfide and suppression of matrix metalloproteinase-9. Our research is generously supported by fundings from the National Institutes of Health and the American Heart Association.
Biography
​Dr. Paras Kumar Mishra is a tenured Associate Professor in the Department of Cellular and Integrative Physiology at the University of Nebraska Medical center (UNMC). He completed his Ph.D. from Banaras Hindu University, India in late 2006 and joined his first postdoctoral fellowship at the Emory University, Atlanta in early 2017. Shortly after his second postdoctoral training from the University of Louisville, Kentucky, he was promoted to Assistant Professor in early 2010. Since 2013, he is continuing his faculty position at the UNMC. His research program focuses on understanding the causes of diabetic heart failure and developing novel strategies to ameliorate it. Several funds, including the American Heart Association and the National Institutes of Health grants have supported his research program. He has served in several study sections of international and national grants, and in editorial board of reputed scientific journals.